Pharmaceutical marketing is one of the most precisely targeted – and most expensive – forms of digital advertising in the world. When a campaign is briefed to reach 50,000 GPs at a quoted CPM of £40, the assumption is straightforward: the budget buys access to 50,000 real, active, doctors.
The reality, for many campaigns running on industry-standard platforms, is significantly different.
The verification gap
A growing body of evidence points to a systemic problem in HCP digital marketing: the audiences being sold to pharmaceutical marketers are routinely inflated by inactive accounts, self-reported credentials and unverified users. The result is a ‘verification gap’ – the distance between the audience you’re quoted and the audience you’re actually reaching.
Analysis of audience data across European HCP platforms reveals the scale of the problem. In one market, out of 112,987 total accounts targeted, only 67,811 were fully validated – just 60% of the quoted audience. Of those, only 57.85% had been active within the last 365 days. The remaining 42.14% were inactive accounts, still sitting in the database, still being counted as reach.
What this means for your budget
The financial consequences are significant. Consider a large-scale GP awareness campaign with a budget of £200,000, targeting 50,000 doctors at a quoted cost per HCP of £4. Once inactive accounts are removed, the real verified active reach drops to 29,000 doctors. The actual cost per HCP — the true cost of reaching a verified, active doctor — rises to £6.89. That’s 73% higher than quoted.
The wasted budget on that single campaign: £84,000 — with your £200,000 delivering just £116,000 in verified reach. The rest disappeared into ghost accounts.
This pattern repeats across campaign types:
- A £75,000 specialist oncology campaign targeting 5,000 oncologists reaches just 2,500 verified, active doctors — doubling the true cost per HCP to £30
- A £50,000 lead generation campaign targeting 500 leads generates only 275, requiring an additional £41,000 just to hit the original target
- A £120,000 multi-touch cardiology campaign reaches 9,000 active doctors instead of 15,000 — with 40% of the audience simply not there
Across these four scenarios alone, the total wasted budget is £210,500 — approximately 47% of the combined investment of £445,000.
The practices driving the problem
Budget waste at this scale doesn’t happen by accident. It is the product of industry-standard practices that have become normalised across many HCP platforms:
- Self-reported professional status with no credential checks against official medical registries
- Simple email verification without medical credential validation
- Outdated databases that are rarely cleaned or updated
- Inactive accounts – often over 40% of the total database – still counted as active reach
- Vague classifications such as ‘probably a doctor’ included in performance metrics
These practices artificially inflate the reach figures platforms quote to clients, creating a gap between the audience promised and the audience delivered.
The question every pharma marketer should be asking
When a platform quotes you 50,000 doctors, the critical question is not how many are in the database – it is how many are fully credential-verified, active in the last 365 days, and checked against an official medical registry.
For UK pharmaceutical marketers, that means asking specifically: how many of your quoted reach are GMC-verified? When were inactive accounts last removed? Do you report verified active reach or total database size?
The answers to those questions will tell you more about the true value of a platform than any quoted CPM figure.
What gold standard looks like
Platforms that apply genuine multilayer verification – checking credentials against official registries such as the UK’s GMC, and transparently reporting activity metrics such as monthly active users (MAU) and yearly active users (YAU) – eliminate this problem entirely.
On M3’s Doctors.net.uk platform, every one of the 270,000+ members is GMC-verified. When a reach figure is quoted, it reflects verified, active doctors. The CPM you’re quoted is the CPM you pay – because the audience behind it is real.
The hidden cost of unverified audiences is not a marginal inefficiency. For many pharmaceutical marketers, it represents the single largest source of wasted budget in their digital mix. The first step to eliminating it is understanding exactly what you are – and are not – paying for.
Download The Hidden Cost of Unverified Audiences white paper
*Data was acquired by Vademecum, part of the Vidal Group which is part of the M3 Group.
